Skyhawk's Proprietary Platform
Small Molecule Therapeutics
for Modifying RNA Expression
Patient Need
26% of human proteins are presently considered to be disease-related; only 3% of human proteins are currently druggable using traditional protein-targeting methods.
Skyhawk’s small molecules can drug these proteins by drugging RNA upstream of the protein, potentially addressing thousands of these historically undruggable targets.
SKYSTAR®, a target assessment system that integrates data from both public and proprietary bioinformatic, structural and computational biology data sets to a prioritize high value RNA targets. We have screened more than 700 targets for Pharma through SKYSTAR.
SKYLIBRARY™, our unique, custom built and rapidly expanding libraries of RNA targeting compounds.
SKYSEQ™, our proprietary multiplex screening system simultaneously tests dozens of high value targets across a range of RNA motifs to identify compounds selective for a specific disease target.
SKYAI™, our machine learning tools, integrating data from SKYSTAR, med chem, animal studies, tox data and clinical programs to drive the next generation of novel RNA splicing modulators.
Skyhawk's platform integrates four distinct and proprietary components in a mutually enhancing way
Skyhawk’s potent small molecule drug candidates target RNA across a broad range of diseases, from orphan and neurological conditions to major cancers.
Skyhawk's platform
offers powerful advantages to patients
Skyhawk’s drug candidates are taken orally, cross the blood brain barrier, and offer therapeutically advantaged, broad, biological distribution.